MX2007006607A - Combinaciones antitumorales que contienen un agente inhibidor de vegf y de 5fu o uno de sus derivados. - Google Patents

Combinaciones antitumorales que contienen un agente inhibidor de vegf y de 5fu o uno de sus derivados.

Info

Publication number
MX2007006607A
MX2007006607A MX2007006607A MX2007006607A MX2007006607A MX 2007006607 A MX2007006607 A MX 2007006607A MX 2007006607 A MX2007006607 A MX 2007006607A MX 2007006607 A MX2007006607 A MX 2007006607A MX 2007006607 A MX2007006607 A MX 2007006607A
Authority
MX
Mexico
Prior art keywords
vegf
vegf inhibitor
combinations
fluorouracil
treatment
Prior art date
Application number
MX2007006607A
Other languages
English (en)
Spanish (es)
Inventor
Jesse M Cedarbaum
Patricia Vrignaud
Marielle Chiron-Blondel
Marie-Christine Bissery
Eric Furfine
Jocelyn Holash
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007006607(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MX2007006607A publication Critical patent/MX2007006607A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2007006607A 2004-12-03 2005-12-02 Combinaciones antitumorales que contienen un agente inhibidor de vegf y de 5fu o uno de sus derivados. MX2007006607A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0412870A FR2878749B1 (fr) 2004-12-03 2004-12-03 Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
PCT/FR2005/003005 WO2006059012A1 (fr) 2004-12-03 2005-12-02 Combinaisons antitumorales contenant un agent inhibiteur de vegf et du 5fu ou un de ses derives

Publications (1)

Publication Number Publication Date
MX2007006607A true MX2007006607A (es) 2007-07-25

Family

ID=34954452

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007006607A MX2007006607A (es) 2004-12-03 2005-12-02 Combinaciones antitumorales que contienen un agente inhibidor de vegf y de 5fu o uno de sus derivados.

Country Status (25)

Country Link
US (3) US20060178305A1 (enExample)
EP (1) EP1824504B1 (enExample)
JP (1) JP4980236B2 (enExample)
KR (1) KR101313404B1 (enExample)
CN (1) CN101068564B (enExample)
AT (1) ATE426409T1 (enExample)
AU (1) AU2005311191C1 (enExample)
BR (1) BRPI0518700B8 (enExample)
CA (1) CA2586735C (enExample)
CY (3) CY1109181T1 (enExample)
DE (1) DE602005013568D1 (enExample)
DK (1) DK1824504T3 (enExample)
ES (1) ES2324233T3 (enExample)
FR (3) FR2878749B1 (enExample)
HR (1) HRP20090336T1 (enExample)
IL (1) IL183481A (enExample)
LU (2) LU92202I2 (enExample)
ME (1) ME01706B (enExample)
MX (1) MX2007006607A (enExample)
PL (1) PL1824504T3 (enExample)
PT (1) PT1824504E (enExample)
RS (1) RS50769B (enExample)
RU (1) RU2384344C2 (enExample)
SI (1) SI1824504T1 (enExample)
WO (1) WO2006059012A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
RS58957B1 (sr) 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
EP3246029A1 (en) * 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN115197948A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-VEGF-Trap、其基因组、制备方法及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9701081D0 (en) * 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
HU230159B1 (hu) * 1999-06-08 2015-09-28 Regeneron Pharmaceuticals, Inc. VEGF receptor kimérák alkalmazása vaszkuláris permeabilitással jellemzett szembetegség kezelésére
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo

Also Published As

Publication number Publication date
CA2586735C (fr) 2014-08-12
JP2008521866A (ja) 2008-06-26
FR2878749B1 (fr) 2007-12-21
CN101068564B (zh) 2010-12-15
BRPI0518700B1 (pt) 2020-02-11
BRPI0518700A2 (pt) 2008-12-02
KR20070091130A (ko) 2007-09-07
CY1109181T1 (el) 2014-07-02
FR2878749A1 (fr) 2006-06-09
RU2384344C2 (ru) 2010-03-20
LU92202I9 (enExample) 2019-01-15
CY2013018I1 (el) 2020-05-29
US8388963B2 (en) 2013-03-05
EP1824504A1 (fr) 2007-08-29
US20060178305A1 (en) 2006-08-10
IL183481A0 (en) 2007-09-20
LU92203I2 (fr) 2013-11-15
US20130184205A1 (en) 2013-07-18
US20090285841A1 (en) 2009-11-19
HRP20090336T1 (hr) 2009-07-31
CN101068564A (zh) 2007-11-07
LU92202I2 (fr) 2013-11-15
RS50769B (sr) 2010-08-31
WO2006059012A1 (fr) 2006-06-08
AU2005311191C1 (en) 2015-04-30
FR13C0024I1 (fr) 2013-05-24
PT1824504E (pt) 2009-06-25
RU2007123607A (ru) 2009-01-10
AU2005311191A1 (en) 2006-06-08
CA2586735A1 (fr) 2006-06-08
JP4980236B2 (ja) 2012-07-18
ME01706B (me) 2010-08-31
ES2324233T3 (es) 2009-08-03
DE602005013568D1 (de) 2009-05-07
KR101313404B1 (ko) 2013-10-01
ATE426409T1 (de) 2009-04-15
IL183481A (en) 2013-09-30
DK1824504T3 (da) 2009-07-20
HK1114769A1 (en) 2008-11-14
CY2013017I1 (el) 2014-07-02
FR13C0025I1 (fr) 2013-05-24
AU2005311191B2 (en) 2011-12-08
BRPI0518700B8 (pt) 2021-05-25
SI1824504T1 (sl) 2009-08-31
LU92203I9 (enExample) 2019-01-15
PL1824504T3 (pl) 2009-08-31
EP1824504B1 (fr) 2009-03-25

Similar Documents

Publication Publication Date Title
US8388963B2 (en) Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof
US20190275147A1 (en) Antitumour combinations containing a vegf inhibiting agent and irinotecan
Bunn Jr et al. Combinations of Three Chemotherapeutic Agents and Two Chemotherapeutic Agents Plus a Targeted Biologic Agent in the Treatment of Advanced Non–Small-Cell Lung Cancer
HK1114769B (en) Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivative
Kerbel et al. Antiangiogenic drugs as broadly effective chemosensitizing agents
HK1141241A (en) Antitumour combinations containing a vegf inhibiting agent and irinotecan
HK1194298A (en) Antitumour combinations containing a vegf inhibiting agent and irinotecan

Legal Events

Date Code Title Description
FG Grant or registration
HH Correction or change in general